Skip to content

Evaluation of DW Silicone Hydrogel Lens Compared to DW Silicone Hydrogel Lens

Evaluation of DW Silicone Hydrogel Lens Compared to DW Silicone Hydrogel Lens

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01386008
Enrollment
28
Registered
2011-06-30
Start date
2011-05-31
Completion date
2011-06-30
Last updated
2019-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopia

Brief summary

The purpose of this study is to evaluate the performance of the investigational CooperVision silicone hydrogel lens compared to a currently-marketed silicone hydrogel contact lens up to 30 days of daily lens wear.

Interventions

DEVICEsenfilcon A contact lens

senofilcon A spherical contact lens worn in a daily wear modality

DEVICEinvestigational enfilcon A

investigational enfilcon A, worn daily wear modality

Sponsors

CooperVision, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Be at least 18 years of age as of the date of evaluation for the study. 2. Not using any ocular medications 3. Have a self-reported full eye examination within 2 years. 4. Have: * read the Informed Consent * be given an explanation of the Informed Consent * indicate understanding of the Informed Consent * signed the Informed Consent document. 5. Be willing and able to adhere to the instructions set forth in this protocol and able to keep all specified appointments. 6. Be an adapted, current full-time silicone hydrogel or soft contact lens wearer. An adapted full-time wearer is defined as wearing contact lenses on a daily basis for at least 8 hours per day for at least one month prior to participation in the study. 7. Possess wearable and visually functional eyeglasses. 8. Be in good general health, based on his/her knowledge. 9. Require spectacle lens powers between -1.00 and -6.00 diopters sphere with no more than 0.75 diopter of refractive astigmatism in order to have the best spherical equivalent power of -6.50 or less. 10. Be willing to wear contact lenses in both eyes. 11. Have manifest refraction Snellen visual acuities (VA) equal to or better than 20/25 (less than or equal to LogMAR 0.10) in each eye. 12. Upon completing the fitting process with the lenses to be worn in the study, have contact lens Snellen VA equal to or better than 20/30 in each eye.

Exclusion criteria

1. Wearing lenses in a monovision modality and is unwilling to be fit with distance lenses in both eyes. NOTE: Subjects may not wear lenses in a monovision modality at any time during the study as it will interfere with the visual acuity analysis. 2. Any active participation in another one-day clinical trial within 7 days prior to this study or another dispensing trial within 30 days prior to this study. 3. Currently pregnant (to the best of the subject's knowledge), is lactating or is planning a pregnancy within the next month. 4. Has a known sensitivity to ingredients used in the over the counter contact lens care approved for use in the study. 5. Previous refractive surgery/anterior segment surgery; or current or previous orthokeratology treatment or irregular cornea. 6. Is aphakic or pseudophakic. 7. Unable to achieve a satisfactory fit with the lens designs used in the study 8. Ocular or systemic disease such as, but not limited to: anterior uveitis or iritis (past or present), glaucoma, Sjögren's syndrome, lupus erythematosus, sclerodermia, keratoconus or type II diabetes. 9. The need for topical ocular medications or any medication which might contradict contact lens wear or which would require the lenses to be removed during the day. 10. The presence of clinically anterior segment infection, inflammations or abnormalities; such as iritis; or any infection of the eye, lids, or associated structures. 11. A history of herpetic keratitis. 12. A known history of corneal hypoesthesia (reduced corneal sensitivity) or active corneal ulcer, corneal infiltrates or fungal infection. 13. A history of papillary conjunctivitis that has interfered with contact lens wear. 14. Slit lamp findings that would contraindicate contact lens wear, including but not limited to: * Pathological dry eye or associated dry eye symptoms with decreased tear levels and punctuate staining \> grade 2 * Pterygium * Corneal scars within the visual axis * Corneal edema or corneal staining ≥ grade 2 * Neovascularization or ghost vessels \> 1.0 mm in from the limbus * Giant papillary conjunctivitis (GPC) of \> grade 2. * Seborrheic eczema, seborrheic conjunctivitis or blepharitis

Design outcomes

Primary

MeasureTime frameDescription
Subjective Comfort Preference - Participants Preference ResponseV1 (Initial), V2 (Day-7), V3 (Day-14), V4 (Day-30)Subjective responses of participants administered by questionnaire and measured on a linear scale (0-100) measured at each visit.
Ocular HealthChange from baseline over 30 days measured at V1 (Initial), V2 (Day-7), V3 (Day-14), V4 (Day-30)Ocular health determined by biomicroscopy recorded on a severity scale (0-4) for change from baseline over 30 days.

Secondary

MeasureTime frameDescription
Investigator Surface PreferenceV1 (Initial), V2 (Day-7), V3 (Day-14), V4 (Day-30)Investigator Surface Preference rated on a linear scale (Lens assessment biomicroscopy: 1=strong R, 2=slight R, 3=No Pref, 4=slight L, 5=strong L)
Investigator Fit PreferenceV1 (Initial), V2 (Day-7), V3 (Day-14), V4 (Day-30)Investigator Fit Preference rated on a linear scale (Lens assessment biomicroscopy: 1=strong R, 2=slight R, 3=No Pref, 4=slight L, 5=strong L)

Countries

United Kingdom, United States

Participant flow

Recruitment details

28 recruited, 4 disqualified due to significant anterior ocular health findings, 4 passed screening and scheduled for lense fit/dispense when study discontinued.

Participants by arm

ArmCount
Overall Study Group
Participants wear one enfilcon A (test) contact lens in one eye and one senofilcon A (comparator) contact lens in the other. Both lenses are worn daily wear.
20
Total20

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyAdverse Event3
Overall Studyexited w/o incident /study discontinued17

Baseline characteristics

CharacteristicOverall Study Group
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
20 Participants
Age, Continuous23 Years
STANDARD_DEVIATION 3
Sex: Female, Male
Female
16 Participants
Sex: Female, Male
Male
4 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
3 / 20
serious
Total, serious adverse events
0 / 20

Outcome results

Primary

Ocular Health

Ocular health determined by biomicroscopy recorded on a severity scale (0-4) for change from baseline over 30 days.

Time frame: Change from baseline over 30 days measured at V1 (Initial), V2 (Day-7), V3 (Day-14), V4 (Day-30)

Population: Not all subjects completed the study measures at each outcome measurement time frame before the study was terminated. 20 participants completed V1 and only 1 participant completed the V2 follow-up. Change from baseline V1 over 30 days V4 cannot be analyzed.

Primary

Subjective Comfort Preference - Participants Preference Response

Subjective responses of participants administered by questionnaire and measured on a linear scale (0-100) measured at each visit.

Time frame: V1 (Initial), V2 (Day-7), V3 (Day-14), V4 (Day-30)

Population: Not all subjects completed the study measures at each outcome measurement time frame before the study was terminated. 20 participants completed V1 and only 1 participant completed the V2 follow-up. V3 and V4 cannot be analyzed.

ArmMeasureGroupValue (NUMBER)
Enfilcon A + Senofilcon ASubjective Comfort Preference - Participants Preference ResponsePreferred Test lens Visit 17 participants
Enfilcon A + Senofilcon ASubjective Comfort Preference - Participants Preference ResponseNo Preference Visit 18 participants
Enfilcon A + Senofilcon ASubjective Comfort Preference - Participants Preference ResponsePreferred Control Lens Visit 15 participants
Enfilcon A + Senofilcon ASubjective Comfort Preference - Participants Preference ResponsePreferred Test lens Visit 20 participants
Enfilcon A + Senofilcon ASubjective Comfort Preference - Participants Preference ResponseNo Preference Visit 21 participants
Enfilcon A + Senofilcon ASubjective Comfort Preference - Participants Preference ResponsePreferred Control lens Visit 20 participants
Secondary

Investigator Fit Preference

Investigator Fit Preference rated on a linear scale (Lens assessment biomicroscopy: 1=strong R, 2=slight R, 3=No Pref, 4=slight L, 5=strong L)

Time frame: V1 (Initial), V2 (Day-7), V3 (Day-14), V4 (Day-30)

Population: Not all subjects completed the study measures at each outcome measurement time frame before the study was terminated. 20 participants completed V1 and only 1 participant completed the V2 follow-up. V3 and V4 cannot be analyzed.

ArmMeasureGroupValue (NUMBER)
Enfilcon A + Senofilcon AInvestigator Fit PreferencePreferred Control Lens V20 participants
Enfilcon A + Senofilcon AInvestigator Fit PreferencePreferred Test Lens V17 participants
Enfilcon A + Senofilcon AInvestigator Fit PreferenceNo Preference V110 participants
Enfilcon A + Senofilcon AInvestigator Fit PreferencePreferred Control Lens V13 participants
Enfilcon A + Senofilcon AInvestigator Fit PreferencePreferred Test Lens V21 participants
Enfilcon A + Senofilcon AInvestigator Fit PreferenceNo Preference V20 participants
Secondary

Investigator Surface Preference

Investigator Surface Preference rated on a linear scale (Lens assessment biomicroscopy: 1=strong R, 2=slight R, 3=No Pref, 4=slight L, 5=strong L)

Time frame: V1 (Initial), V2 (Day-7), V3 (Day-14), V4 (Day-30)

Population: Not all subjects completed the study measures at each outcome measurement time frame before the study was terminated. 20 participants completed V1 and only 1 participant completed the V2 follow-up. V3 and V4 cannot be analyzed.

ArmMeasureGroupValue (NUMBER)
Enfilcon A + Senofilcon AInvestigator Surface PreferencePreferred Test Lens V16 participants
Enfilcon A + Senofilcon AInvestigator Surface PreferenceNo Preference V15 participants
Enfilcon A + Senofilcon AInvestigator Surface PreferencePreferred Control Lens V19 participants
Enfilcon A + Senofilcon AInvestigator Surface PreferencePreferred Test Lens V20 participants
Enfilcon A + Senofilcon AInvestigator Surface PreferenceNo Preference V21 participants
Enfilcon A + Senofilcon AInvestigator Surface PreferencePreferred Control Lens V20 participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026